Cargando…

Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching Hospital

OBJECTIVE: To evaluate efficacy, safety and utilization pattern of deferasirox in paediatric patients of transfusion dependant β Thalassemia Major at a tertiary care teaching hospital in Gujarat. MATERIALS AND METHODS: This observational, prospective-retrospective, single centre, continuous study wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thakor, Dhaval R, Desai, Chetna K, Kapadia, Jigar D, Dikshit, Ram K, Mehariya, KM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582544/ https://www.ncbi.nlm.nih.gov/pubmed/28900315 http://dx.doi.org/10.4103/ijmpo.ijmpo_103_16

Ejemplares similares

Transfusion-related adverse reactions in pediatric and surgical patients at a tertiary care teaching hospital in India
por: Ghataliya, Kunal J., et al.
Publicado: (2017)

An analysis of serious adverse drug reactions at a tertiary care teaching hospital
por: Prajapati, Kinjal, et al.
Publicado: (2016)

Efficacy and safety of anti-tuberculosis drugs in HIV-positive patients: A prospective study
por: Kapadia, Jigar D., et al.
Publicado: (2013)

Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha
por: Panigrahi, Mousumee, et al.
Publicado: (2020)

A Survey of Knowledge, Attitude, and Practice of Consumers at a Tertiary Care Hospital Regarding the Disposal of Unused Medicines
por: Sonowal, Supriya, et al.
Publicado: (2016)

An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital
por: Desai, Chetna K., et al.
Publicado: (2011)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Tenofovir induced Fanconi syndrome: A possible pharmacokinetic interaction
por: Kapadia, Jigar, et al.
Publicado: (2013)

An evaluation of trigger tool method for adverse drug reaction monitoring at a tertiary care teaching hospital
por: Menat, Urmila, et al.
Publicado: (2021)

PB2540: HEPATIC SAFETY PROFILE OF DEFERASIROX IN CHILDREN WITH BETA THALASSEMIA MAJOR IN OMAN
por: Almadhani, Shaimaa, et al.
Publicado: (2023)

Deferasirox in Indian children with thalassemia major: 3 years experience
por: Dhamija, Mayank, et al.
Publicado: (2013)

Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials
por: Xia, Sujian, et al.
Publicado: (2013)

An evaluation of trigger tool method for adverse drug reaction monitoring at a tertiary care teaching hospital
por: Gohil, Jaydipsinh B, et al.
Publicado: (2022)

The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan
por: Chang, Hsiu-Hao, et al.
Publicado: (2015)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review
por: Salem, Ahmed, et al.
Publicado: (2023)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
por: Ricchi, Paolo, et al.
Publicado: (2015)

Comparison of contrast sensitivity in β-thalassemia patients treated by deferoxamine or deferasirox
por: Ghazanfari, Azam, et al.
Publicado: (2019)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
por: Adramerina, Alkistis, et al.
Publicado: (2022)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study
por: Tartaglione, Immacolata, et al.
Publicado: (2020)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major
por: Ejaz, Muzamil Shabana, et al.
Publicado: (2015)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
por: Hagag, Adel A., et al.
Publicado: (2013)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
por: Galeotti, Laura, et al.
Publicado: (2021)

Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy
por: Soliman, Ashraf, et al.
Publicado: (2014)

Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major
por: Pathare, Anil, et al.
Publicado: (2009)

Efficacy of varenicline versus bupropion for smoking cessation: A systematic review and meta-analysis of randomized controlled trials
por: Patel, Ashish R., et al.
Publicado: (2023)

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing
por: Buaboonnam, Jassada, et al.
Publicado: (2021)

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2017)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study
por: Badeli, Hamidreza, et al.
Publicado: (2019)

An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient With Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection
por: Chauhan, Devkishan, et al.
Publicado: (2021)

Pleasures and pains of running a pharmacovigilance center
por: Dikshit, R.K., et al.
Publicado: (2008)

An evaluation of the impact of antidiabetic medication on treatment satisfaction and quality of life in patients of diabetes mellitus
por: Chaturvedi, Richa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_r0e90ejlv3h2uijbtoiv5hc7kj